Market Research Report

Global Rare Neurodegenerative Disease Treatment Market Report By Indication (Multiple Sclerosis (MS), Alzheimer’s Disease, Parkinson's Disease, Acute Migraine, Autism, Narcolepsy, Amyotrophic Lateral Sclerosis (ALS), Attention Deficit Hyperactivity Disorder (ADHD), Spinal Muscular Atrophy, Tourette Syndrome, Huntington's Disease, Others), By Drug Class (Neurotransmitter Agents, Neuroprotective Agents, Biologics, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028

ID:VMR11215028
May 2021
Report Formats: Electronic (PDF), MS EXCEL

The global demand for Rare Neurodegenerative Disease Treatment Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.

Neurodegenerative diseases mainly refer to gradual damage to nerve cells in different parts of the human body. These disorders, including Alzheimer’s disease, ADHD, and ALS, Parkinson’s disease, can lose memory and cognitive control. Though cures for such conditions are very narrow, the pharmaceutical sector has launched several treatment offerings to minimize the symptoms of neurodegenerative diseases over the years. 

Market Dynamics 

The rise in prevalence and increase in demand for newer drugs to treat rare neurological disorders has led to an increase in research & development efforts followed by introducing innovative neurological disorder drugs. In addition, an increase in demand for neurological disorder drugs for the treatment of Alzheimer’s disease and Parkinson’s disease and a rise in competition between major players are likely to boost the growth of the market. However, the cost of neurological disorder treatment is considerably high, owing to the large quantity of antiepileptic, anticholinergic, and hypnotic & sedatives required. This is likely to impede the global rare neurodegenerative disease treatment market.

The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rare neurodegenerative disease treatment. The growth and trends of rare neurodegenerative disease treatment industry provide a holistic approach to this study. 

Market Segmentation

This section of the rare neurodegenerative disease treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Indication

  • Multiple Sclerosis (MS)
  • Alzheimer’s Disease
  • Parkinson's Disease
  • Acute Migraine
  • Autism
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Spinal Muscular Atrophy
  • Tourette Syndrome
  • Huntington's Disease
  • Others


By Drug Class

  • Neurotransmitter Agents
  • Neuroprotective Agents
  • Biologics
  • Others


By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies


Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Rare Neurodegenerative Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

Global Rare Neurodegenerative Disease Treatment Market Share by Region (Representative Graph)

Global Rare Neurodegenerative Disease Treatment Market Share

 

Know more about this report: Download free sample

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the rare neurodegenerative disease treatment market include Allergan Plc, Bayer AG, F.Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
 
METHODOLOGY:

This market research report has been produced by gathering information based on primary and secondary research. Secondary research has been done using various sources, including (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications. Additionally, our team conducts extensive primary research with key industry participants to gather first-hand data. The data is then analyzed and validated by industry experts.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE
     1.1. Report Description
        1.1.1. Objective
        1.1.2. Target Audience
        1.1.3. Unique Selling Proposition (USP) & offerings
     1.2. Research Scope
     1.3. Research Methodology
        1.3.1. Market Research Process
        1.3.2. Market Research Methodology
 
2. EXECUTIVE SUMMARY
     2.1. Highlights of Market
     2.2. Global Market Snapshot
 
3. RARE NEURODEGENERATIVE DISEASE TREATMENT – INDUSTRY ANALYSIS
     3.1. Introduction - Market Dynamics
     3.2. Market Drivers
     3.3. Market Restraints
     3.4. Opportunities
     3.5. Industry Trends
     3.6. Porter’s Five Force Analysis
     3.7. Market Attractiveness Analysis
        3.7.1 By Indication
        3.7.2 By Drug Class
        3.7.3 By Distribution Channel
        3.7.4 By Region
 
4. VALUE CHAIN ANALYSIS
     4.1. Value Chain Analysis
     4.2. Raw Material Analysis
        4.2.1. List of Raw Materials
        4.2.2. Raw Material Manufactures List
        4.2.3. Price Trend of Key Raw Materials
     4.3. List of Potential Buyers
     4.4. Marketing Channel
        4.4.1. Direct Marketing
        4.4.2. Indirect Marketing
        4.4.3. Marketing Channel Development Trend
 
5. IMPACT ANALYSIS OF COVID-19 OUTBREAK
     5.1. Impact Analysis of Covid-19 Outbreak
        5.1.1. Direct Impact on Production
        5.1.2. Supply Chain and Market Disruption
        5.1.3. Financial Impact on Firms and Financial Markets
     5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
     5.3. Market: Pre V/S Post COVID-19
     5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic 
     5.5. COVID-19: Micro and Macro Factor Analysis
 
6. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET ANALYSIS BY INDICATION
     6.1 Overview by Indication
     6.2 Historical and Forecast Data
     6.3 Analysis by Indication
     6.4 Multiple Sclerosis (MS) Market by Regions
     6.5 Alzheimer’s Disease Market by Regions
     6.6 Parkinson's Disease Market by Regions
     6.7 Acute Migraine Market by Regions
     6.8 Autism Market by Regions
     6.9 Narcolepsy Market by Regions
     6.10. Amyotrophic Lateral Sclerosis (ALS) Market by Regions
     6.11 Attention Deficit Hyperactivity Disorder (ADHD) Market by Regions
     6.12 Spinal Muscular Atrophy Market by Regions
     6.13 Tourette Syndrome Market by Regions
     6.14 Huntington's Disease Market by Regions
 
7. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET ANALYSIS BY DRUG CLASS
     7.1 Overview by Drug Class
     7.2 Historical and Forecast Data
     7.3 Analysis by Drug Class
     7.4 Neurotransmitter Agents Market by Regions
     7.5 Neuroprotective Agents Market by Regions
     7.6 Biologics Market by Regions
     7.7 Others Market by Regions
 
8. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL
     8.1 Overview by Distribution Channel
     8.2 Historical and Forecast Data
     8.3 Analysis by Distribution Channel
     8.4 Hospital Pharmacies Market by Regions
     8.5 Online Pharmacies Market by Regions
     8.6 Retail Pharmacies Market by Regions
 
9. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY
     9.1. Regional Outlook
     9.2. Introduction
     9.3. North America
        9.3.1. Overview, Historic and Forecast Data 
        9.3.2. North America By Segment
        9.3.3. North America By Country
        9.3.4. United State
        9.3.5. Canada
        9.3.6. Mexico
     9.4. Europe
        9.4.1. Overview, Historic and Forecast Data 
        9.4.2. Europe by Segment
        9.4.3. Europe by Country
        9.4.4. United Kingdom
        9.4.5. France
        9.4.6. Germany
        9.4.7. Italy
        9.4.8. Russia
        9.4.9. Rest Of Europe
     9.5. Asia Pacific
        9.5.1. Overview, Historic and Forecast Data 
        9.5.2. Asia Pacific by Segment
        9.5.3. Asia Pacific by Country
        9.5.4. China
        9.5.5. India
        9.5.6. Japan
        9.5.7. South Korea
        9.5.8. Australia
        9.5.9. Rest Of Asia Pacific
     9.6. Latin America
        9.6.1. Overview, Historic and Forecast Data 
        9.6.2. Latin America by Segment
        9.6.3. Latin America by Country
        9.6.4. Brazil
        9.6.5. Argentina
        9.6.6. Peru
        9.6.7. Chile
        9.6.8. Rest of Latin America
     9.7. Middle East & Africa
        9.7.1. Overview, Historic and Forecast Data 
        9.7.2. Middle East & Africa by Segment
        9.7.3. Middle East & Africa by Country
        9.7.4. Saudi Arabia
        9.7.5. UAE
        9.7.6. Israel
        9.7.7. South Africa
        9.7.8. Rest Of Middle East And Africa
 
10. COMPETITIVE LANDSCAPE OF THE RARE NEURODEGENERATIVE DISEASE TREATMENT COMPANIES
     10.1. Rare Neurodegenerative Disease Treatment Market Competition
     10.2. Partnership/Collaboration/Agreement
     10.3. Merger And Acquisitions
     10.4. New Product Launch
     10.5. Other Developments
 
11. COMPANY PROFILES OF RARE NEURODEGENERATIVE DISEASE TREATMENT INDUSTRY
     11.1. Company Share Analysis
     11.2. Market Concentration Rate
     11.3. Allergan Plc
        11.3.1. Company Overview
        11.3.2. Financials
        11.3.3. Products
        11.3.4. Recent Developments
     11.4. Bayer AG
        11.4.1. Company Overview
        11.4.2. Financials
        11.4.3. Products
        11.4.4. Recent Developments
     11.5. F.Hoffmann-La Roche Ltd.
        11.5.1. Company Overview
        11.5.2. Financials
        11.5.3. Products
        11.5.4. Recent Developments
     11.6. GlaxoSmithKline plc
        11.6.1. Company Overview
        11.6.2. Financials
        11.6.3. Products
        11.6.4. Recent Developments
     11.7. Johnson & Johnson
        11.7.1. Company Overview
        11.7.2. Financials
        11.7.3. Products
        11.7.4. Recent Developments
     11.8. Merck KGaA
        11.8.1. Company Overview
        11.8.2. Financials
        11.8.3. Products
        11.8.4. Recent Developments
     11.9. Novartis AG
        11.9.1. Company Overview
        11.9.2. Financials
        11.9.3. Products
        11.9.4. Recent Developments
     11.10. Pfizer Inc.
        11.10.1. Company Overview
        11.10.2. Financials
        11.10.3. Products
        11.10.4. Recent Developments
     11.11. Sanofi
        11.11.1. Company Overview
        11.11.2. Financials
        11.11.3. Products
        11.11.4. Recent Developments
     11.12. Teva Pharmaceutical Industries Ltd.
        11.12.1. Company Overview
        11.12.2. Financials
        11.12.3. Products
        11.12.4. Recent Developments
 
 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • COVID-19 Impact Analysis by Production, Import, Export and Demand
  • Pre V/S Post COVID-19
  • Estimated Impact Of The Coronavirus (Covid-19) Epidemic
  • COVID-19: Micro and Macro Factor Analysis
  • Analysis by Indication (USD MN)
  • Multiple Sclerosis (MS) Market by Geography (USD MN)
  • Alzheimer’s Disease Market by Geography (USD MN)
  • Parkinson's Disease Market by Geography (USD MN)
  • Acute Migraine Market by Geography (USD MN)
  • Autism Market by Geography (USD MN)
  • Narcolepsy Market by Geography (USD MN)
  • Amyotrophic Lateral Sclerosis (ALS) Market by Geography (USD MN)
  • Attention Deficit Hyperactivity Disorder (ADHD) Market by Geography (USD MN)
  • Spinal Muscular Atrophy Market by Geography (USD MN)
  • Tourette Syndrome Market by Geography (USD MN)
  • Huntington's Disease Market by Geography (USD MN)
  • Analysis Market by Drug Class (USD MN)
  • Neurotransmitter Agents Market by Geography (USD MN)
  • Neuroprotective Agents Market by Geography (USD MN)
  • Biologics Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market by Geography (USD MN)
  • Online Pharmacies Market by Geography (USD MN)
  • Retail Pharmacies Market by Geography (USD MN)
  • Global Rare Neurodegenerative Disease Treatment Market by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisiton

 
LIST OF FIGURES
 

  • Research Scope of Rare Neurodegenerative Disease Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Rare Neurodegenerative Disease Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Indication (USD MN)
  • Multiple Sclerosis (MS) Market by Geography (USD MN)
  • Alzheimer’s Disease Market by Geography (USD MN)
  • Parkinson's Disease Market by Geography (USD MN)
  • Acute Migraine Market by Geography (USD MN)
  • Autism Market by Geography (USD MN)
  • Narcolepsy Market by Geography (USD MN)
  • Amyotrophic Lateral Sclerosis (ALS) Market by Geography (USD MN)
  • Attention Deficit Hyperactivity Disorder (ADHD) Market by Geography (USD MN)
  • Spinal Muscular Atrophy Market by Geography (USD MN)
  • Tourette Syndrome Market by Geography (USD MN)
  • Huntington's Disease Market by Geography (USD MN)
  • Global Market Analysis by Drug Class (USD MN)
  • Neurotransmitter Agents Market by Geography (USD MN)
  • Neuroprotective Agents Market by Geography (USD MN)
  • Biologics Market by Geography (USD MN)
  • Others Market by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market by Geography (USD MN)
  • Online Pharmacies Market by Geography (USD MN)
  • Retail Pharmacies Market by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Company Market Share Analysis

 
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Why Choose Us

Client First Policy
Excellent Quality
After Sales Support
24/7 Email Support

Clients

Testimonials